Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis

Tsagias N, Koliakos I, Karagiannis V, Eleftheriadou M, Koliakos GG . Isolation of mesenchymal stem cells using the total length of umbilical cord for transplantation purposes. Transfus Med 2011; 21: 253–261.

Liang L, Dong C, Chen X, Fang Z, Xu J, Liu M et al. Human umbilical cord mesenchymal stem cells ameliorate mice trinitrobenzene sulfonic acid (TNBS)-induced colitis. Cell Transplant 2011; 20: 1395–1408.

González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M . Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009; 136: 978–989.

González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M . Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009; 60: 1006–1019.

Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42–49.

Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004; 104: 3581–3587.

Wojakowski W, Tendera M . Mobilization of bone marrow-derived progenitor cells in acute coronary syndromes. Folia Histochem Cytobiol 2005; 43: 229–232.

Chamberlain G, Fox J, Ashton B, Middleton J . Mesenchymal stem cells: their phenotype, differentiation capacity, immunological features and potential for homing. Stem Cells 2007; 25: 2739–2749.

Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I . The role of mesenchymal stem cells in haemopoiesis. Blood Rev 2006; 20: 161–171.

Schenk S, Mal N, Finan A, Zhang M, Kiedrowski M, Popovic Z et al. MCP-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007; 25: 245–251.

Ryan JM, Barry F, Murphy JM, Mahon BP . Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353–363.

Kwon KH, Murakami A, Hayashi R, Ohigashi H . Interleukin-1β targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Biochem Biophys Res Commun 2005; 337( 2): 647–654.

Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R . A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694–702.

Arai Y, Takanashi H, Kitagawa H, Okayasu I . Involvement of interleuking-1 in the development of ulceratie colitis inducted by dextran sulfate sodiium in mice. Cytokine 1998; 10: 890–896.

Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010; 59: 1192–1199.

Lebeis SL, Powell KR, Merlin D, Sherman MA, Kalman D . Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium. Infect Immun 2009; 77: 604–614.

Kojouharoff G, Hans W, Obermeier F, Männel DN, Andus T, Schölmerich J et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997; 107: 353–358.

González-Navajas JM, Law J, Nguyen KP, Bhargava M, Corr MP, Varki N et al. Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production. J Exp Med 2010; 207: 2799–2807.

Martin M, Neumann D, Hoff T, Resch K, DeWitt DL, Goppelt-Struebe M . Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int 1994; 45: 150–158.

Mizel SB, Dayer JM, Krane SM, Mergenhagen SE . Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc Natl Acad Sci U S A 1981; 78: 2474–2477.

Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002; 109: 883–893.

Nitta M, Hirata I, Toshina K, Murano M, Maemura K, Hamamoto N et al. Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329. Scand J Immunol 2002; 56: 66–75.

Cominelli F, Nast CC, Llerena R, Dinarello CA, Zipser RD . Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. J Clin Invest 1990; 85: 582–586.

Groh ME, Maitra B, Szekely E, Koç ON . Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005; 33: 928–934.

Liu CH, Hwang SM . Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 2005; 32: 270–279.

Lasigliè D, Traggiai E, Federici S, Alessio M, Buoncompagni A, Accogli A et al. Role of IL-1 beta in the development of human TH17 cells: lesson from NLPR3 mutated patients. PLoS One 2011; 6: e20014.

Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Shi S et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009; 183: 7787–7798.

Gonzalez-Rey E, Anderson P, González MA, Rico L, Büscher D, Delgado M . Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009; 58: 929–939.

Kao AP, Wang KH, Long CY, Chai CY, Tsai CF, Hsieh TH et al. Interleukin-1β induces cyclooxygenase-2 expression and promotes the invasive ability of human mesenchymal stem cells derived from ovarian endometrioma. Fertil Steril 2011; 96: 678–684.

Ji JF, He BP, Dheen ST, Tay SS . Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells 2004; 22: 415–427.

Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008; 16: 571–579.

Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141–150.

Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, de Bruyn C, Meuleman N et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 2010; 264: 171–179.

Romieu-Mourez R, François M, Boivin MN, Bouchentouf M, Spaner DE, Galipeau J . Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009; 182: 7963–7973.

Bouffi C, Bony C, Courties G, Jorgensen C, Noël D . IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. Plos One 2010; 5: e14247.

Pricola KL, Kuhn NZ, Haleem-Smith H, Song Y, Tuan RS . Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem 2009; 108: 577–588.